Navigation Links
Secrets of lung cancer drug resistance revealed at UCSF
Date:7/2/2012

People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will returnit's a question of when. And for far too many, it happens far too soon.

Now, a team of researchers at the University of California, San Francisco's Helen Diller Family Comprehensive Cancer Center has discovered that a human protein called AXL drives resistance to Tarceva, which suggests that blocking the protein may prevent resistance to the cancer drug.

The discovery, described this week in Nature Genetics, may lead to better treatments involving precision medicines that would combine Tarceva with new drugs designed to block AXL.

"If we block AXL activation in the laboratory, we can overcome resistance to Tarceva," said Trever Bivona, MD, PhD, an assistant professor of hematology and oncology. "This paves the way for novel and more effective therapies."

In the experiments, Bivona and his colleagues used an inhibitor of AXL that is not an ideal clinical drug. But now Bivona and his team are working together with Kevan Shokat, PhD, a Howard Hughes Medical Institute Investigator and chair of the UCSF Department of Cellular and Molecular Pharmacology, to develop more potent AXL inhibitors for clinical testing.

Lung Cancer is Number One Cancer Killer

Lung cancer is the most common cause of cancer death worldwide. More people die from the disease each year than from breast, colon and prostate cancers combined. It claims more than 150,000 American lives annually and accounts for some 1.4 million deaths around the world. About 85 percent of Americans with all types of lung cancer die within five years of diagnosis.

Most cases result from exposure to cigarette smoke, but other causes include exposure to asbestos, chemicals, environmental factors and genetic susceptibility.

One thing that makes lung cancer so difficult is that it often goes undetected in its early stages because it usually does not cause symptoms. Only about 30 percent of patients in the United States are detected in the earliest stage of the disease, contributing to its low overall survival rate.

Even people who have their cancer detected at the earliest stages, however, face serious odds. Unlike other types of cancer, where early diagnosis has significant survival advantages, some 35 to 45 percent of people with stage I lung cancer die within five years of recurrent disease.

Though treatment varies depending on the type of lung cancer, its stage, and whether it not it has metastasized to regional lymph nodes, standard treatments usually involve surgery or some combination of surgery, radiation therapy and chemotherapy.

Tarceva is one such chemotherapy drug. Also known as erlotinib, the drug is a targeted therapy that works by blocking an enzyme known as epidermal growth factor receptor (EGFR). Bivona and his colleagues discovered that AXL drives resistance to Tarceva by "rescuing" lung cancers from EGFR inhibitor treatment.

AXL, said Bivona, is the sort of molecule known as a kinase, which makes it a valuable target for drug design. Many of the existing targeted cancer drugs on the market, including Tarceva, work by blocking kinases in one form or another.


'/>"/>

Contact: Jason Socrates Bardi
jason.bardi@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. Dotcomsecrets is Offering New Opportunities to People Who Want to Become Expert in Localized Internet Marketing
2. DotComSecrets Invites Professionals to Learn Great Tips On How to Make a Handsome Income By Working As Local Internet Marketing Consultants
3. 13 Free Weight Loss Secrets Program Kicks-Off
4. DotComSecrets Offers Free Webinar to Make Individuals Skilled in Earning Thousands of Dollars by Becoming DCS’s Local Consultant
5. DotComSecrets’ Russell Brunson Is Revealing Online Money Making Secrets in Free Webinars for Students
6. DotComSecrets Is Seeking Local DCS Consultants Through Free Webinars in Coming Days
7. Study Suggests Vaccine May Help Kids With Brain Cancer
8. New Stool Test Might Aid in Early Detection of Colon Cancer
9. Study reveals how cancer drug causes diabetic-like state
10. How a cancer drug leads to diabetes
11. You Survived Cancer: Now Pay Attention to Your Overall Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Secrets of lung cancer drug resistance revealed at UCSF
(Date:1/17/2017)... ... 17, 2017 , ... Metro Development Group has broken ground ... technology into the fabric of an entire community. A highlight of this new ... in a yet-to-be-named, health focused campus. Leading this initiative in partnership with Metro ...
(Date:1/17/2017)... Lehi, Utah (PRWEB) , ... January 17, 2017 ... ... provider of accredited, online continuing education for EMS and firefighting professionals, has released ... Training (VILT) Solution. These new courses are taught live in an online classroom ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting process ... , the Cradle to Cradle Products Innovation Institute has announced. , This ... through early 2018. The challenges are presented by the Institute in partnership with Autodesk ...
(Date:1/17/2017)... CO (PRWEB) , ... January 17, 2017 , ... ... protection and financial planning assistance to families and business professionals throughout central Colorado, ... to regional homeless families. , The Aurora Warms The Night organization is committed ...
(Date:1/17/2017)... ... 17, 2017 , ... Seceon , the only threat ... today announced a strategic partnership with TechLab Security, a leading Enterprise ... TechLab Security has become a strategic partner and a value added reseller of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... , Jan. 17, 2017  CSSi, the global leader ... clinical research industry, will exhibit at the 8 th ... (SCOPE 2017), taking place from Tuesday, January 24 - ... in Miami, FL. ... technology platform, SmartStudy™ EMR, which provides a revolutionary look ...
(Date:1/17/2017)... York , January 17, 2017 Transparency ... (Cinnamic Acid, Benzoic Acid, Sodium Benzoate, Benzyl Alcohol and Others) Market ... According to the report, the global benzaldehyde derivative market ... to reach US$ 2.14 Bn by 2024, expanding at a CAGR ... ...
(Date:1/17/2017)... 17, 2017  Bayer today announced the appointment of Dr. ... in the Americas, comprising the United States ... Latin America . In this role, Dr. Brunn will ... of Management of Bayer AG and President of the Pharmaceutical ... leader in the pharmaceutical industry and I,m delighted to have ...
Breaking Medicine Technology: